ArticleEmerging infectious diseases2014
Human antibody responses to avian influenza A(H7N9) virus, 2013.
Article in Emerging infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.The Journal of infectious diseases · 2016Trial
- Reduced T cell epitope cross-conservation and immunogenic potential is associated with emergence of a dominant influenza subclade K in 2025.Human vaccines & immunotherapeutics · 2026Article
- Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice.Human vaccines & immunotherapeutics · 2022Article
- COVID-19 vaccine design using reverse and structural vaccinology, ontology-based literature mining and machine learning.Briefings in bioinformatics · 2022Article
- Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.Emerging microbes & infections · 2021Article
- Human antibody recognition of H7N9 influenza virus HA following natural infection.JCI insight · 2021Article
- AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets.NPJ vaccines · 2021Article
- Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering.Computational and structural biotechnology journal · 2021Article
- A Host-Restricted Self-Attenuated Influenza Virus Provides Broad Pan-Influenza A Protection in a Mouse Model.Frontiers in immunology · 2021Article
- The kinetics of humoral response and its relationship with the disease severity in COVID-19.Communications biology · 2020Article
- Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus.PLoS biology · 2020Article
- Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge.Human vaccines & immunotherapeutics · 2020Article
- Rational Design of SARS-CoV-2 Spike Glycoproteins To Increase Immunogenicity By T Cell Epitope Engineering.bioRxiv : the preprint server for biology · 2020Article
- Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans.The Journal of infection · 2020Article
- Persistence of H7N9 virus antibody response 2 years after infection.Influenza and other respiratory viruses · 2020Article
- Characterization of antibody and memory T-cell response in H7N9 survivors: a cross-sectional analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2020Article
- H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets.NPJ vaccines · 2020Article
- Novel Avian Influenza A Virus Infections of Humans.Infectious disease clinics of North America · 2019Review
- H7N9 influenza A virus activation of necroptosis in human monocytes links innate and adaptive immune responses.Cell death & disease · 2019Article
- Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans.Nature microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding host antibody response is crucial for predicting disease severity and for vaccine development. We investigated antibody responses against influenza A(H7N9) virus in 48 serum samples from 21 patients, including paired samples from 15 patients. IgG against subtype H7 and neutralizing antibodies (NAbs) were not detected in acute-phase samples, but ELISA geometric mean titers increased in convalescent-phase samples; NAb titers were 20-80 (geometric mean titer 40). Avidity to IgG against subtype H7 was significantly lower than that against H1 and H3. IgG against H3 was boosted after infection with influenza A(H7N9) virus, and its level in acute-phase samples correlated with that against H7 in convalescent-phase samples. A correlation was also found between hemagglutinin inhibition and NAb titers and between hemagglutinin inhibition and IgG titers against H7. Because of the relatively weak protective antibody response to influenza A(H7N9), multiple vaccinations might be needed to achieve protective immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.